Market-access agreements for anti-cancer drugs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.BMC public health · 2025
   Article
2. Uptake and availability of new outpatient cancer medicines in 2010-2021 in Nordic countries - survey of competent authorities.BMC health services research · 2023
   Article
3. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.JAMA health forum · 2023
   Article
4. Cost and public reimbursement of cancer medicines in the UK and the Republic of Ireland.Irish journal of medical science · 2023
   Article
5. Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria.Frontiers in public health · 2023
   Article
6. Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.BMC health services research · 2022
   Article
7. Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America.Applied health economics and health policy · 2022
   Article
8. Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?Journal of the Royal Society of Medicine · 2020
   Review
9. Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'.PharmacoEconomics · 2020
   Article
10. Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy.Journal of market access & health policy · 2018
    Article
11. Immunotherapies for advanced melanoma: as promising as they are expensive?Journal of the Royal Society of Medicine · 2017
    Article
12. Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?Journal of the Royal Society of Medicine · 2017
    Article
13. Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future.Frontiers in pharmacology · 2017
    Article
14. Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?PharmacoEconomics · 2016
    Article
15. Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?PharmacoEconomics · 2016
    Article
16. Access to new cancer medicines in Australia: dispelling the myths and informing a public debate.Journal of pharmaceutical policy and practice · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as